Clinical trials: Throat Carcinoma
Cancer-related Fatigue
A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy
Eighty to 90% of SCCHN (squamous cell carcinoma of head and neck) patients in Taiwan were betel quid chewers. Thirty to 40% of them experienced mucositis World Health Organization (WHO) grade 3 from cisplatin/flurouracil (FU) in…
- Trial name
- NCT01720563
- Testing
- Astragalus polysaccharides 500 mg, Concurrent chemoradiotherapy with PUL (cisplatin/tegafur plus uracil (UFT)/leucovorin) every 2 weeks
- Where
- Taiwan
- Volunteers
- 17 people
- Sponsor
- PhytoHealth Corporation
Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma
Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma
Gemcitabine plus cisplatin (GC) is more effective than fluorouracil plus cisplatin in the treatment of recurrent or metastatic NPC (R/M-NPC). GC is the standard first-line chemotherapy regimen for this population.
- Trial name
- NCT03639467
- Testing
- Anlotinib plus gemcitabine/cisplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese Academy of Medical Sciences
Nasopharyngeal Carcinoma
To Investigate the Molecular Mechanism of Traditional Chinese Medicine Constitution Using Next-generation Sequencing in Nasopharyngeal Carcinoma
To investigate the molecular mechanism of traditional Chinese medicine constitution, the investigators proposed a randomized, double-blind, placebo-controlled, phase II trial to recruit 120 patients with nasopharyngeal cancer.
- Trial name
- NCT03578575
- Testing
- Danggui Buxue Tang
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- China Medical University Hospital
Nasopharyngeal Carcinoma
A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA
Nasopharyngeal carcinoma (NPC) is a geographically endemic, Epstein-Barr virus (EBV)-associated carcinoma of epidermoid origin. It occurs most commonly in Southern China and Southeast Asia.
- Trial name
- NCT02363400
- Testing
- MEP
- Where
- 6 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- National Health Research Institutes, Taiwan
Oropharyngeal Cancer, Dysphagia, Oropharyngeal
Liposomal Bupivacaine and Transoral Robotic Surgery
This study is for patients with oropharyngeal squamous cell carcinoma. We want to learn more about how we can optimize pain control in patients who undergo transoral robotic surgery (TORS) for oropharyngeal squamous cell…
- Conditions
- Oropharyngeal Cancer, Dysphagia, Oropharyngeal, Post Operative Pain, Transoral Robotic Surgery
- Trial name
- NCT05862792
- Testing
- Liposomal bupivacaine
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Geisinger Clinic
Nasopharyngeal Carcinoma
Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to compare concurrent chemoradiotherapy plus adjuvant chemotherapy with concurrent chemoradiotherapy in patients with locoregionally advanced NPC, in order to evaluate the value of adjuvant…
- Trial name
- NCT00677118
- Testing
- Cisplatin,fluorouracil, Cisplatin
- Where
- China
- Volunteers
- 506 people
- Sponsor
- Sun Yat-sen University
Cervical Cancer, Head and Neck Squamous Cell Carcinoma
HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor
A single center, open, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 TCR-T cell for HPV18 positive advanced solid tumor.
- Conditions
- Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Cancer, Vagina Tumor
- Trial name
- NCT05787535
- Testing
- Fludarabine + Cyclophosphamide, HRYZ-T101 TCR-T Cell
- Where
- China
- Volunteers
- 17 people
- Sponsor
- HRYZ Biotech Co.
Nasopharyngeal Carcinoma, Chemotherapy
Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that concurrent and adjuvant PD-1 treatment added to concurrent chemo-radiotherapy could further decrease the rate of disease progression and…
- Conditions
- Nasopharyngeal Carcinoma, Chemotherapy, Radiotherapy, PD-1 Treatment
- Trial name
- NCT04453813
- Testing
- Toripalimab plus concurrent chemo-radiotherapy, Concurrent chemo-radiotherapy
- Where
- 6 sites in China
- Volunteers
- 226 people
- Sponsor
- Sun Yat-sen University
Oropharyngeal Cancer, Oral Cancer
Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis.
Radiotherapy with or without adjuvant chemotherapy represents an important column of modern therapy in advanced squamous cell originated tumours of the head and neck.
- Conditions
- Oropharyngeal Cancer, Oral Cancer, Lymph Node Metastasis
- Trial name
- NCT00964977
- Testing
- Radiation therapy
- Where
- 49 sites in Germany, Netherlands and 1 more
- Volunteers
- 209 people
- Sponsor
- Johannes Gutenberg University Mainz
Analgesia, Surgery
Postoperative Pain, Why Still in Hospital and DAOH Following TORS for SCCUP & OSAS
This protocol investigates the effect of a high dose dexamethasone regimen in the treatment of postoperative pain following Transoral Robotic Surgery (TORS). The protocol consists of three substudies. 1.
- Conditions
- Analgesia, Surgery, Cancer of Head and Neck, Oropharyngeal Cancer
- Trial name
- NCT04189107
- Testing
- Dexamethasone
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Nasopharyngeal Carcinoma
Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy
Currently, concurrent chemoradiotherapy with/without sequential chemotherapy is the standard treatment modality for intermediate risk NPC (stage II and T3N0M0) according to the National Comprehensive Cancer Network guideline.
- Trial name
- NCT02289807
- Testing
- Cisplatin, IMRT
- Where
- China
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
Patients will be treated with pembrolizumab after concurrent chemoradiotherapy with cisplatin. Patients will be treated with up to 17 cycles (approximately 1 year) of pembrolizumab until disease progression or recurrence
- Trial name
- NCT04227509
- Testing
- Pembrolizumab
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Seoul National University Hospital
Nasopharyngeal Carcinoma
Retrospective Study About Nasopharyngeal Carcinoma at C. S. Parc Tauli
Retrospective study of patients diagnosed with a nasopharyngeal carcinoma included in our data base care between June 1990 and September 2013.
- Trial name
- NCT02199132
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Corporacion Parc Tauli
Oropharynx Cancer
Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma
The Phase III study will include 174 patients with locally advanced oropharynx carcinoma, receiving all arc-IMRT (Intensity-Modulated Radiation Therapy) (70 Gy) with concomitant systemic therapy.
- Trial name
- ARTIX (NCT01874587)
- Testing
- adaptative radiotherapy
- Where
- 11 sites in France
- Volunteers
- 132 people
- Sponsor
- Center Eugene Marquis
Nasopharyngeal Carcinoma, Iron-deficiency
Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma
Primary purpose： To evaluate the difference of hematopoietic response rate at 1 month after concurrent chemoradiotherapy between iron isomaltide and oral iron supplement for treating iron-deficiency anemia patients with locally…
- Conditions
- Nasopharyngeal Carcinoma, Iron-deficiency, Anemia
- Trial name
- NCT05913414
- Testing
- Iron Isomaltoside 1000, Polysaccharide Iron Complex Pill, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Neoplasms
Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal Carcinoma
This is a single center, non-randomized phase IIa study to determine the tolerance and safety of Abraxane (ABX) in combination with cisplatin (DDP) in patients with advanced nasopharyngeal carcinoma (NPC).
- Trial name
- ABX-DDP-Dose (NCT01735409)
- Testing
- ABX + DDP
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Sun Yat-sen University
Recurrent, Nasopharyngeal Carcinoma
Treatment Result of KTP Laser Nasopharyngectomy in Recurrent NPC Patients
Investigate the treatment result of KTP laser nasopharyngectomy in recurrent NPC patients
- Trial name
- NCT00364962
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Recurrent Nasopharyngeal Carcinoma
Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
A multicenter randomized controlled study of surgery combined with neoadjuvant and adjuvant therapy for locally advanced recurrent nasopharyngeal carcinoma in comparison to surgery combined with adjuvant therapy
- Trial name
- NCT06235203
- Testing
- endoscopic surgery, Neoadjuvant therapy,Toripalimab Injection and Gemcitabine based therapy, Adjuvant therapy in experimental group,Toripalimab Injection and Gemcitabine based therapy
- Where
- 7 sites in China
- Volunteers
- 154 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Oral Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma
Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
To evaluate the design, safety and efficacy of OralViome Cancer Testing system in the early detection of Oral and Throat Cancers using saliva metatranscriptomic analysis.
- Conditions
- Oral Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Premalignant Lesion
- Trial name
- NCT05451303
- Testing
- OralViome Cancer Testing System
- Where
- United States
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- Viome
Nasopharyngeal Carcinoma
Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma
A total of 120 patients with pathologically confirmed locally advanced low-risk nasopharyngeal carcinoma were enrolled. They were randomly divided into two groups, with 60 patients in each group.
- Trial name
- NCT02237924
- Testing
- endostar, DDP, IMRT
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.